| http://www.w3.org/ns/prov#value | - Studying Warfarin, Valium and other compounds still under development, Xceleron found the mass-balance curves for microdoses and ordinary doses closely overlap.Xceleron now has a small U.S. office where Scott Tarrant is VP of business development.
|
